Related Experiment Video

Updated: Jul 18, 2026

Pull-down of Calmodulin-binding Proteins
07:51

Pull-down of Calmodulin-binding Proteins

Published on: January 23, 2012

Targeting calmodulin in reversing multi drug resistance in cancer cells

Y C Mayur1, S Jagadeesh, K N Thimmaiah

  • 1Department of Medicinal Chemistry, V.L. College of Pharmacy, Raichur, India. mayuryc@rediffmail.com

Mini Reviews in Medicinal Chemistry
|December 16, 2006
PubMed

Insights

Calmodulin, a key calcium-binding protein, regulates cellular processes. Inhibiting calmodulin can reverse multi-drug resistance (MDR) in cancer cells, offering new therapeutic strategies.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Calmodulin is a crucial calcium-binding protein mediating diverse cellular signaling pathways in eukaryotes.
  • It regulates vital processes like mitosis and muscle contraction by modulating numerous enzymes.
  • Multi-drug resistant cancer cells exhibit higher intracellular calcium, increasing their susceptibility to calmodulin antagonists.

Purpose of the Study:

  • To review the identification and optimization of novel calmodulin inhibitors.
  • To explore the potential of these inhibitors in reversing multi-drug resistance (MDR) in cancer cells.

Main Methods:

  • Review of existing literature on calmodulin antagonists and their mechanisms.
  • Analysis of various pharmacological agents, including verapamil, phenothiazines, phenoxazines, and acridones, as calmodulin inhibitors.
  • Investigation of the impact of calmodulin antagonism on multi-drug resistance in cancer models.

Main Results:

  • Calmodulin antagonists, such as phenothiazines and their bioisosteres, effectively inhibit calmodulin.
  • These antagonists demonstrate the ability to modulate multi-drug resistance in cancer cells.
  • Increased intracellular calcium in resistant cells enhances their sensitivity to calmodulin antagonism.

Conclusions:

  • Calmodulin inhibitors represent a promising strategy for overcoming multi-drug resistance in cancer.
  • Further research into the identification and optimization of novel calmodulin antagonists is warranted for therapeutic development.

Related Concept Videos

Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...